Femasys
Femasys' revenue rose 40.8% to $2 million in fiscal 2025. Its operating margin was −767.0%, up from −1,091.8% a year earlier. Free cash flow was −$19 million. The diluted share count rose 77.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Femasys lost money in fiscal 2025: a net loss of $19 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 25 | 13 | 22 | 4 | 9 |
| Debt incl. finance leases | 0 | 0 | 4 | 0 | 3 |
| Net debt (negative means net cash) | −25 | −13 | −17 | −4 | −6 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.2x | 0.0x | 0.5x |
| Interest coverage | −433.6x | −861.6x | −87.7x | −11.1x | −9.3x |
| Current ratio | 15.2x | 9.2x | 7.6x | 0.9x | 4.5x |
| Quick ratio | 15.0x | 9.0x | 7.4x | 0.6x | 3.0x |
Cash flow
Projections
Project Femasys' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $74,000 of Femasys shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Kathy Lee-SepsickChief Executive Officer, Director | Bought | 15,625 | $3.20 | $50,000 | Form 4 |
| Aug 7, 2026 | John Charles CanningChief Operating Officer | Bought | 4,375 | $3.20 | $14,000 | Form 4 |
| Aug 7, 2026 | Jeremy Alexander SiposChief Technology Officer | Bought | 3,125 | $3.20 | $10,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 3 of 9 | 2 of 9 |
| Rule of 40 | −1,076.9% | −1,188.3% | −797.1% |
| Altman Z'' | −9.44 | −42.98 | −24.17 |
| Accruals ratio | −13.3% | 3.1% | 0.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 3 of 9 | 2 of 9 |
Compare
Put Femasys side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Femasys | FY25 | 40.8% | −767.0% | −837.9% | — | — | 2 | |
| Anteris Technologies Global | FY25 | −29.2% | −4,908.2% | −4,169.2% | — | — | — | Compare |
| Neuraxis | FY25 | 32.9% | −219.4% | −181.1% | — | — | — | Compare |
| Intelligent Bio Solutions | FY26 | 38.1% | −299.1% | −285.9% | — | — | — | Compare |
| Lucid Diagnostics | FY25 | 8.3% | −1,054.8% | −992.0% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1 | 1 | 1 | 1 | 2 | 2 |
| Revenue growth | — | 13.7% | 2.2% | −11.1% | 52.0% | 40.8% |
| Gross profit | 1 | 1 | 1 | 1 | 1 | 1 |
| Research and development | 4 | 4 | 6 | 7 | 8 | 8 |
| Operating income | −7 | −8 | −12 | −14 | −18 | −18 |
| Net income | −7 | −8 | −11 | −14 | −19 | −19 |
| Diluted EPS (US$) | −7.20 | −1.12 | −0.96 | −0.93 | −0.85 | −0.47 |
| Diluted shares (millions) | 1 | 7 | 12 | 15 | 22 | 40 |
| Cash flow | ||||||
| Cash from operations | −5 | −8 | −11 | −11 | −19 | −19 |
| Capital expenditure | 0 | 0 | 0 | 0 | 1 | 0 |
| Free cash flow | −5 | −8 | −11 | −11 | −20 | −19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 1 | 0 | 1 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 3 | 25 | 13 | 22 | 4 | 9 |
| Debt incl. finance leases | 1 | 0 | 0 | 4 | 0 | 3 |
| Total assets | 8 | 29 | 17 | 28 | 12 | 21 |
| Total liabilities | 4 | 2 | 2 | 9 | 10 | 15 |
| Shareholders' equity | −52 | 26 | 15 | 18 | 2 | 6 |
| Margins and ratios | ||||||
| Gross margin | 70.5% | 68.6% | 63.4% | 64.5% | 66.5% | 62.0% |
| Operating margin | −668.0% | −706.7% | −961.7% | −1,353.4% | −1,091.8% | −767.0% |
| Net margin | −666.2% | −639.0% | −944.6% | −1,329.1% | −1,155.0% | −812.3% |
| Free cash flow margin | −476.1% | −698.3% | −923.5% | −1,065.7% | −1,240.3% | −837.9% |
| Rule of 40 (growth + FCF margin) | — | −684.6% | −921.2% | −1,076.9% | −1,188.3% | −797.1% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | −54.8% | −84.8% | −182.2% | −455.8% |
| Return on assets | — | −41.7% | −50.1% | −63.8% | −93.6% | −112.3% |
| Net debt to EBITDA | — | — | — | — | — | — |